?? Why This Matters
OECD Test Guidelines represent the global gold standard for chemical and pharmaceutical safety testing. These internationally harmonized methods are legally accepted across 38 member countries plus dozens of partner economies, covering over 80% of global GDP and pharmaceutical markets.
The Mutual Acceptance of Data (MAD) agreement means test once, submit everywhere—companies can conduct a single study following OECD TG protocols and use that data for regulatory submissions in the US, EU, Japan, China, and all other MAD signatories. This saves industry an estimated ?? €309 million annually while eliminating hundreds of thousands of duplicative animal tests.
?? PROGRAM OVERVIEW
The OECD Test Guidelines Programme develops internationally harmonized test methods for assessing chemical safety. These guidelines are accepted by all 38 OECD member countries plus partner economies under the Mutual Acceptance of Data (MAD) agreement, eliminating duplicative testing and enabling global market access with single studies.
Established in 1981, the program operates through the Working Group of the National Coordinators of the Test Guidelines Programme (WNT), which coordinates validation, peer review, and adoption of new test methods across member states.
?? PROGRAM HISTORY TIMELINE
?? KEY PRINCIPLES (Plain English)
1. Mutual Acceptance of Data (MAD)
The cornerstone principle: test data from one country is legally accepted in all MAD signatory countries without needing additional studies. If you test a chemical according to OECD TG 439 in Germany, the US EPA, Japanese MHLW, and all other regulatory authorities must accept those results. This eliminates the need to repeat identical tests in different jurisdictions.
2. Good Laboratory Practice (GLP) Requirement
For MAD benefits to apply, studies must be conducted in GLP-certified facilities following OECD GLP Principles (C(81)30). GLP ensures data quality, integrity, and reproducibility through rigorous documentation, quality assurance, and facility inspections. Non-GLP studies following TGs have scientific value but lack automatic regulatory acceptance.
3. Performance-Based Test Guideline (PBTG) Approach
For in vitro methods, OECD uses performance-based validation—instead of prescribing a single protocol, TGs define performance standards (sensitivity, specificity, reproducibility) that alternative methods must meet. This allows innovation: if a new reconstructed skin model meets TG 439 performance standards, it's automatically acceptable without needing a separate guideline.
4. Validation Through International Centers
New test methods undergo rigorous multi-laboratory validation coordinated by EURL ECVAM (Europe), ICCVAM (US), or JaCVAM (Japan). Validation includes within-lab reproducibility, between-lab transferability, predictive capacity vs. reference data, and applicability domain definition. Only methods passing peer review by international experts progress to TG adoption.
5. Regular Updates and Revisions
Test Guidelines are living documents, not static regulations. OECD updates TGs as new scientific knowledge emerges, technologies improve, or validation data expands applicability domains. Users must check the current version (indicated by adoption/revision date) to ensure compliance.
6. No Preference for In Vivo Over In Vitro
OECD Test Guidelines give equal regulatory standing to validated in vitro and in vivo methods. Regulators cannot reject in vitro data simply because an animal test exists—if the NAM is fit-for-purpose and follows the TG, it must be accepted. This principle is critical for replacing animal studies with organ chips and other advanced platforms.
?? COMPARISON: OECD TG vs Regional Pathways
| Feature | OECD TG | FDA ISTAND | EMA 3Rs | EPA NAMs |
|---|---|---|---|---|
| Primary Focus | Chemical safety (industrial, cosmetics, pesticides) | Drug development tools (pharmaceuticals) | Medicines/biologics (broad 3Rs application) | Environmental chemicals, pesticides |
| Geographic Reach | ?? 38 countries + partners (global) | ???? US only | ???? EU 27 member states | ???? US only |
| Legal Mandate | ? MAD treaty (must accept data) | Strong presumption (not absolute) | Directive 2010/63/EU requirement | TSCA/FIFRA statutory basis |
| Timeline to Adoption | 5-10 years (rigorous validation) | 2-4 years (expedited) | Varies (case-by-case) | 3-7 years |
| Validation Rigor | Very high (multi-lab, international) | Moderate (fit-for-purpose) | Moderate to high | High |
| Cost to Validate Method | ?? $10-25M (multi-lab studies) | $3-8M | Variable | $5-15M |
| Organ Chip Inclusion | ?? Under evaluation (2024-2027) | ? Active (2+ qualified) | Emerging (pilot studies) | Strategic priority (2023+) |
| Best For | ?? Global market access, established methods | US pharma, cutting-edge tech | EU medicines compliance | US environmental regs |
?? KEY IN VITRO GUIDELINES
- TG 497: Defined Approaches for Skin Sensitisation—integrated testing strategies combining DPRA, KeratinoSens, h-CLAT for full LLNA replacement
- TG 498: In Vitro Phototoxicity Test using reconstructed human epidermis for UV-induced skin reactions
- TG 442C/D/E: Skin Sensitisation in chemico and in vitro methods (DPRA, KeratinoSens, h-CLAT)×modular tests for allergic contact dermatitis
- TG 439: In Vitro Skin Irritation using reconstructed human epidermis (EpiDerm, SkinEthic)×replaces rabbit Draize test
- TG 492: Reconstructed Human Cornea-like Epithelium (RhCE) for eye irritation—alternative to rabbit eye tests
- TG 455/456: Stably Transfected Transactivation assays for estrogen/androgen receptor agonists/antagonists—endocrine disruption screening
- TG 487: In Vitro Mammalian Cell Micronucleus Test—genotoxicity assessment using human cells
- TG 431: In Vitro Skin Corrosion using reconstructed human epidermis—chemical burn potential
?? OECD TG COMPLIANCE CHECKLIST
Use this checklist when conducting studies for global regulatory submissions:
?? Study Planning
? Check for most recent TG version/update
? Verify test method included in TG (for PBTGs)
? Review applicability domain limitations
? Confirm GLP facility certification current
? Ensure test system meets TG requirements
? Obtain reference/control substances
?? GLP Compliance
? Develop approved study protocol
? Document all deviations immediately
? Maintain raw data with traceability
? Ensure QA unit independent audits
? Archive materials per GLP timeline
? Follow TG-specified endpoints exactly
?? Test Execution
? Use test system within passage range (cells)
? Document environmental conditions
? Follow exact TG exposure duration
? Apply acceptance criteria to controls
? Repeat if acceptance criteria not met
? Photograph/image document as required
?? Data Analysis
? Apply prediction model as defined
? Calculate all required parameters
? Check data against historical controls
? Classify result per TG criteria
? Note borderline/equivocal results
? Archive statistical software version
?? Reporting
? Cite specific test method (if PBTG)
? Report all deviations with justification
? Provide GLP compliance statement
? Include QA audit dates/findings
? Append study protocol & amendments
? Archive study for MAD requirements
?? MAD Submission
? Verify country has MAD status
? Include GLP monitoring authority statement
? Translate key sections if required
? Submit through national contact point
? Retain English-language version
? Prepare for questions from regulators
?? IMPACT ON INDUSTRY
Chemical Manufacturers
OECD TGs enable simultaneous global market access through MAD. A single GLP study following TG protocols satisfies REACH (EU), TSCA (US), CSCL (Japan), K-REACH (Korea), and 30+ other national chemical registration requirements without duplicative testing.
Cosmetics Industry
EU's 2013 animal testing ban for cosmetics drove adoption of OECD reconstructed tissue models. Brands can now prove safety using TG 439 (skin irritation), TG 492 (eye irritation), and TG 431 (corrosion) without animal tests, enabling sales across all MAD countries.
Contract Research Organizations
CROs invest heavily in GLP certification and OECD TG method implementation to offer globally accepted testing services. Facilities demonstrating proficiency in multiple TGs command premium pricing and attract multinational clients needing MAD-compliant data.
Technology Developers
Companies developing novel in vitro platforms pursue OECD TG inclusion through PBTG validation. Success transforms a proprietary research tool into a globally accepted regulatory method, dramatically expanding commercial market.
Pharmaceutical Industry
While pharma relies more on FDA/EMA pathways than OECD TGs for drug-specific testing, companies use OECD genotoxicity and endocrine assays (TG 487, TG 455) for early screening and impurity testing where global harmonization matters.
?? MUTUAL ACCEPTANCE OF DATA (MAD)
Under the 1981 MAD Council Decision, safety data generated using OECD Test Guidelines in one member country must be accepted by all other members. This saves industry an estimated €309 million annually, eliminates redundant animal studies, and accelerates global chemical and pharmaceutical approvals.
Current MAD Signatories: 38 OECD member countries plus Argentina, Brazil, India, Malaysia, Singapore, South Africa, and Thailand as adherents. Together representing >85% of global chemical commerce and pharmaceutical markets.
?? VALIDATION PROCESS
New test methods undergo rigorous validation through EURL ECVAM, ICCVAM, or JaCVAM before OECD adoption. The process includes within-laboratory reproducibility, transferability studies, predictive capacity assessment, and formal peer review—typically requiring 5-10 years from method development to guideline adoption.
Validation Steps: (1) Catch-up validation using existing data, (2) Within-lab reproducibility (3 labs minimum), (3) Between-lab transferability (5+ labs), (4) Performance assessment vs. reference data, (5) Peer review by international experts, (6) WNT adoption vote, (7) Publication as OECD TG with unique number.
?? REAL-WORLD TG ADOPTION CASE STUDIES
Case Study 1: EpiDerm® Skin Irritation Model (MatTek)
Challenge: Replace the rabbit Draize skin irritation test (OECD TG 404) with a human-relevant in vitro alternative acceptable worldwide.
Approach: MatTek Corporation developed EpiDerm®, a reconstructed human epidermis model, and pursued PBTG inclusion in TG 439. Validation coordinated by EURL ECVAM included 15 laboratories testing 60 reference chemicals across 3 continents (2003-2006).
Validation Results: Within-lab reproducibility: 95%; between-lab reproducibility: 89%1; predictive accuracy vs. rabbit data: 84% sensitivity, 82% specificity. Performance met PBTG standards established by OECD expert working group.
Timeline: Initial development (1999), pre-validation (2001-2003), formal validation (2003-2006), OECD TG 439 adoption including EpiDerm (2010), multiple model updates added to TG (2013, 2015).
Commercial Impact: Post-TG inclusion, EpiDerm sales increased 520% as global chemical/cosmetics companies adopted the platform for routine compliance testing. MatTek expanded to 8 international distributors, generating $45M+ annual revenue. Model now accounts for 70% of global in vitro skin irritation testing under OECD TG 439.
Regulatory Acceptance: Data accepted by ECHA (REACH), EPA (TSCA), PMDA (Japan), NMPA (China), and 30+ national authorities through MAD agreement. Enabled cosmetics companies to meet EU animal testing ban while maintaining global market access.
Key Success Factors: Robust multi-lab validation, clear performance standards, commercial availability of materials, comprehensive training programs, strong IP protection allowing commercial scale-up.
Case Study 2: DPRA Skin Sensitization Assay (TG 442C)
Challenge: Replace the mouse Local Lymph Node Assay (LLNA) for identifying allergic contact dermatitis hazards—a test using thousands of mice annually for cosmetics/chemicals safety.
Approach: Procter & Gamble developed the Direct Peptide Reactivity Assay (DPRA), an in chemico method measuring chemical reactivity with skin proteins. Submitted to OECD through US ICCVAM pathway (2009).
Validation Results: Ring trial across 12 laboratories in US, Europe, Japan tested 82 reference chemicals. Accuracy: 80% for GHS UN classification. Method demonstrated as first component of Defined Approach for complete LLNA replacement when combined with KeratinoSens and h-CLAT.
Timeline: Method development (2004-2008), ICCVAM pre-validation (2009-2011), international validation (2011-2013), OECD TG 442C adoption (2015), integration into TG 497 Defined Approaches (2018).
Impact on Animal Testing: DPRA as part of TG 497 DAs enabled elimination of LLNA for most chemical/cosmetics applications. Estimated reduction: 45,000 mice/year in Europe alone. US EPA formally accepted DPRA data for TSCA submissions (2016).
Industry Adoption: By 2020, 80% of cosmetics companies used DPRA-based strategies. Commercial DPRA kits from multiple vendors (Givaudan, Cosmetics Europe) enabled routine testing at $800-1,200 per chemical vs. $15,000-25,000 for LLNA. Unilever, L'Oréal, Procter & Gamble integrated into internal safety cascades.
Lessons Learned: In chemico methods can achieve regulatory acceptance if mechanistically justified through AOP framework. Combination approaches (Defined Approaches) overcome limitations of individual assays. Strong industry consortium support accelerated validation and adoption.
Case Study 3: Liver MPS Hepatotoxicity Submission (Pending)
Context: Multiple companies developing liver microphysiological systems (MPS) for drug-induced liver injury (DILI) prediction sought OECD TG pathway to enable global regulatory acceptance (2019-2024).
Technical Challenges: Unlike simple endpoint assays (e.g., skin irritation), liver MPS generate complex multi-parameter data (viability, enzyme release, bile transport, metabolic competence). Lack of consensus on which endpoints constitute "positive" for hepatotoxicity. Platform-to-platform variability in cell sources (primary vs. iPSC), culture duration (3d vs. 14d), media formulations.
Regulatory Concerns: OECD WNT reviewers questioned: (1) Applicability domain—do results in hepatocytes predict whole-liver toxicity? (2) Transferability—can methods be reproduced in non-developer labs? (3) Performance standards—what sensitivity/specificity vs. clinical data is acceptable?
Current Status (2024): OECD established expert working group on "Organ-on-Chip Methods for Hepatotoxicity" but has not initiated formal validation. Consensus: technology promising but standardization insufficient for TG development. Recommendation: pursue FDA ISTAND qualification for specific contexts of use first, then leverage that data for OECD submission.
Alternative Path Forward: Industry consortium (IQ MPS Affiliate) developing standardized protocols and performance benchmarks. Plan: demonstrate cross-lab reproducibility through pre-competitive studies, then submit as Performance-Based Test Guideline allowing multiple platforms meeting shared standards.
Key Lessons: Complex technologies require MORE standardization than simple assays for OECD acceptance. Pursue regional qualifications (FDA ISTAND, EMA 3Rs) first to build validation data package. Industry consensus standards critical before OECD submission. Timeline expectations: 2025-2030 for first organ chip TGs.
?? STRATEGIC ROADMAP: Getting Your Method into OECD TG
Phase 1: Pre-Development Assessment (Year 1)
Market Analysis: Identify regulatory need your method addresses. Is there existing animal test causing bottlenecks? Regulatory pressure for alternatives (cosmetics ban, 3Rs mandates)? Size global market for this testing type.
Technical Feasibility: Does method measure mechanistically relevant endpoints? Can it be standardized across laboratories? Are materials commercially available at scale? Estimated cost per test vs. current standard?
Competitive Landscape: Are other methods in OECD pipeline for same application? Can you differentiate through performance, cost, throughput, or applicability domain?
IP Strategy: File patents on core technology but prepare to license openly for validation. OECD strongly prefers methods available to all stakeholders without restrictive licensing.
Go/No-Go Decision Point: Estimated validation cost $10-25M. Market size must justify investment. Consider consortium funding model (IQ Consortium, Cosmetics Europe) to share costs.
Phase 2: Method Optimization & Pilot Testing (Years 2-3)
Protocol Standardization: Document exact procedures, materials, equipment. Define critical vs. non-critical parameters. Develop Standard Operating Procedures (SOPs) suitable for GLP environments.
Reference Chemical Selection: Assemble 50-100 reference chemicals with known in vivo results. Include diverse chemical classes, potencies, edge cases. Obtain materials meeting GLP requirements.
Within-Lab Reproducibility: Run triplicate studies with blinded operators. Calculate precision, accuracy, sensitivity, specificity. Target: >90% reproducibility, >80% accuracy vs. reference data.
Technology Transfer: Transfer method to 2-3 independent laboratories. Identify sticking points. Revise SOPs. Develop training materials. This pilot reveals transferability issues before expensive formal validation.
Phase 3: Engage Validation Authorities (Year 3-4)
Validation Center Selection: Approach EURL ECVAM (Europe), ICCVAM (US), or JaCVAM (Japan). Submit pre-validation dossier including pilot data, SOPs, scientific rationale, commercial availability plan.
Catch-Up Validation: Validation center reviews existing data against OECD performance standards. Identifies gaps. May request additional studies before formal validation. Budget 12-18 months for this phase.
Scientific Advisory Committee: OECD convenes expert panel to review mechanistic basis, applicability domain, limitations. Provide AOP linkage if available. Prepare for critical questions about relevance to human safety.
OECD Notification: Once validation center commits, notify OECD Test Guidelines Programme. Method added to WNT work plan, signaling to member countries and industry that validation underway.
Phase 4: Formal Validation Studies (Years 4-6)
Multi-Lab Ring Trial: 5-12 independent GLP laboratories conduct blinded studies using coded chemicals. Coordinated by validation center. Each lab tests full reference set (~80 chemicals). Study design follows OECD validation principles.
Performance Evaluation: Statistical analysis of between-lab reproducibility, predictive capacity, false positive/negative rates. Comparison vs. existing reference method (often animal test). Applicability domain defined by chemical space tested.
Cost: $10-25M depending on complexity. Includes lab fees ($150K-300K per participating lab), materials, statistical analysis, report generation. Typically funded by technology developer, industry consortium, or government grants (SBIR, Horizon Europe).
Peer Review: Validation report submitted to OECD expert panel. Public comment period (60-90 days). Address reviewer concerns through additional studies if needed. Revision cycles can extend timeline 6-12 months.
Phase 5: TG Adoption & Commercial Launch (Years 7-8)
WNT Adoption Process: Method presented to Working Group of National Coordinators. Member countries vote on TG adoption. Requires consensus (no formal opposition). Political considerations: Does method reduce animal use? Cost-effective? Widely applicable?
TG Publication: Upon adoption, OECD publishes Test Guideline with unique number (e.g., TG 442C). Includes detailed protocol, acceptance criteria, performance standards (if PBTG), applicability domain, limitations.
GLP Implementation: CROs and industry labs implement method in GLP environments. Technology developer provides training, materials, technical support. Establish commercial supply chain for all required reagents/materials.
Market Launch: Promote globally accepted method to industry. Target sectors: cosmetics, chemicals, pharma. Emphasize MAD benefits: single study accepted worldwide. Typical adoption curve: 20-30% industry penetration year 1, 60-80% by year 5 for high-value applications.
Post-Adoption Support: OECD periodically updates TGs. Maintain engagement with WNT to address issues, expand applicability domain, add new similar methods to PBTG. Plan for 10+ year lifecycle management.
?? GLOBAL SUBMISSION STRATEGY: Leveraging MAD
How to maximize value of OECD TG data for worldwide regulatory approvals:
Strategy 1: Single-Study Multi-Jurisdiction Filing
Conduct OECD TG study in any MAD signatory country under GLP. Use data for simultaneous submissions to ECHA (REACH), EPA (TSCA), PMDA (Japan), NMPA (China), and other authorities. Savings: Avoid duplicative testing, reduce timeline 12-18 months vs. sequential country-specific studies, eliminate need for multi-regional CRO contracts.
Example: Chemical company conducts TG 439 skin irritation study at German GLP lab (€2,500 cost). Data accepted by US EPA, ECHA, Japan MHLW, Korea MOE, and 15 other jurisdictions for product registrations—total value €35,000+ if tested separately.
Strategy 2: Defined Approach Optimization
For endpoints with multiple DAs (e.g., TG 497 offers 4 skin sensitization approaches), select DA matching your chemical space. 2 out of 3 Rule: If two DA components predict same outcome, third test can be skipped per TG 497 guidance. Reduces cost 30-40% while maintaining MAD acceptance.
Cost Optimization: DPRA ($1,200) + KeratinoSens ($2,800) = $4,000 for 2-test DA vs. $8,000 full 3-test battery. If both predict "sensitizer," regulators accept conclusion without h-CLAT per TG 497.
Strategy 3: Strategic GLP Lab Selection
Choose GLP facilities in countries with strong MAD compliance records and multiple bilateral agreements. Germany, Netherlands, US, Japan have excellent regulatory track records. Avoid newly-acceded MAD countries where authorities may be less familiar with mutual acceptance principles.
Red Flag: Some non-MAD countries (e.g., Brazil pre-2017) may reject OECD TG data if not conducted domestically. Check country-specific requirements before study initiation if targeting those markets.
Strategy 4: Proactive Regulator Engagement
For novel applications of existing TGs (e.g., using TG 487 for gene therapy impurities), engage regulators via pre-submission consultations. While MAD mandates acceptance, clarifying context of use prevents post-submission questions. Submit brief scientific justification 3-6 months before filing.
Best Practice: US FDA offers pre-IND meetings, ECHA has screening consultations, PMDA offers pre-application consultations—all free services to confirm OECD TG study design before execution.
?? FREQUENTLY ASKED QUESTIONS
?? KEY TAKEAWAYS FOR STAKEHOLDERS
OECD Test Guidelines provide the regulatory foundation for global chemical commerce. Whether you're testing products, developing technologies, conducting research, or providing services, understanding this system is essential for navigating international markets efficiently.
For Chemical/Cosmetics Companies
OECD Test Guidelines are your passport to global markets. A single GLP study following TG protocols provides data accepted in 38+ countries through MAD, eliminating duplicative testing that can cost hundreds of thousands of euros. Focus on in vitro TGs (439, 492, 497) for cosmetics to comply with animal testing bans while maintaining international sales. For new chemical registrations (REACH, TSCA, K-REACH), OECD TG data is the gold standard regulators expect. Investment in understanding applicable TGs during product development prevents costly regulatory delays.
For Technology Developers
Getting your in vitro platform into an OECD Test Guideline transforms it from research tool to regulatory standard, unlocking massive commercial value. Plan for 5-10 year timeline and $10-25M validation investment—but success can generate $50M+ annual revenue as industry adopts your method globally. Partner early with validation centers (ECVAM, ICCVAM), build commercial supply chain, establish IP protection while maintaining open licensing for validation. Focus on addressing clear regulatory needs (replacing costly/controversial animal tests) where performance standards can be clearly defined. Organ chip developers: pursue FDA ISTAND first to build validation data before OECD submission.
For Pharmaceutical Companies
While pharma primarily follows ICH guidelines, strategic use of OECD TGs saves time and money in specific applications. Use genotoxicity TGs (487, 473, 476) for ICH M7 impurity qualification—globally accepted data from single study. Leverage endocrine assays (455/456) for safety pharmacology assessments. For excipient safety (skin/eye irritation), OECD in vitro TGs provide human-relevant data faster than animal studies. When developing novel drug modalities (gene therapies, mRNA vaccines), engage FDA/EMA early to clarify which OECD TGs are acceptable for your specific context of use.
For Contract Research Organizations
OECD TG implementation under GLP is premium-priced, high-margin business. Companies need MAD-compliant data and will pay 30-50% premium vs. non-GLP testing for regulatory certainty. Investment priorities: GLP certification for facilities, training staff on latest TG updates, implementing Performance-Based Test Guidelines to offer multiple method options, maintaining current versions of all TGs (regularly updated). Market differentiation: offer consultative services helping clients select optimal TG strategies (e.g., Defined Approaches for cost savings), provide data packages formatted for multi-jurisdiction submissions, maintain expertise in emerging areas (organ chips, AOPs, IATAs).
For Academic Researchers
Academia provides innovation engine for next-generation TGs but faces structural challenges translating research to regulation. Most impactful contributions: develop mechanistic assays with clear AOP linkage, publish validation-ready protocols (detailed SOPs, reference chemicals, acceptance criteria), contribute to AOP-Wiki building mechanistic foundations, participate in pre-competitive consortia (IQ, HESI) bridging academic-industry-regulatory gaps. For career development, expertise in OECD validation processes creates consulting opportunities and positions on expert panels. Most successful translation path: publish proof-of-concept academically, then license/partner with commercial entity for validation phase requiring resources beyond typical academic funding.
Looking Ahead: OECD TGs 2025-2030
Next frontier for OECD Test Guidelines: complex in vitro models and computational approaches. Organ-on-chip systems for hepatotoxicity, nephrotoxicity, and cardiotoxicity will likely achieve TG status 2026-2028 as standardization improves. Defined Approaches will expand to more endpoints, combining in silico, in chemico, and in vitro data for comprehensive hazard assessment without animals. QSAR and read-across methods will gain formal TG status with clear applicability domains. Expect increased emphasis on human-relevant models using iPSC-derived cells rather than animal-derived tissues. The MAD framework will expand to include more partner countries (India, Southeast Asia) as global chemical commerce grows. Industry should monitor WNT work program and engage early in draft TG consultations to shape methods meeting real-world needs.
Bottom Line: OECD Test Guidelines represent the most successful international harmonization effort in chemical safety regulation. Understanding and leveraging this system—whether as test user, method developer, or academic researcher—provides competitive advantage in an increasingly global, sustainability-focused regulatory environment. The shift from animal to human-relevant in vitro methods is accelerating, creating opportunities for innovation while maintaining the scientific rigor and mutual acceptance that make OECD TGs the global gold standard.